{
    "clinical_study": {
        "@rank": "164721", 
        "arm_group": [
            {
                "arm_group_label": "pelubiprofen (30mg) tablet IR TID, fasting", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "pelubiprofen (30mg) tablet IR TID, fed", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized, open-labeled, comparative 3-way crossover study to compare the pharmacokinetic\n      characteristics and food effect of pelubiprofen (30mg) tablet IR TID and pelubiprofen SR (as\n      a pelubiprofen 90 mg) tablet QD in healthy subjects."
        }, 
        "brief_title": "Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects", 
        "completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult Healthy males aged 20~45 years\n\n          2. weight over 45 kg, ideal body weight \u00b120%[Ideal weight] = [Height(cm)-100] X 0.9\n\n          3. Subjects who voluntarily agreed with written consent\n\n        Exclusion Criteria:\n\n          1. Patients with acute disorder within 28 days before clinical trial drugs\n             administration\n\n          2. History of disorders(inflammatory GI tract disease, stomach ulcer, gastrectomy, liver\n             disease) which can affect ADME of drugs\n\n          3. Patients with active GI tract, cardiovascular, respiratory, renal, endocrinal,\n             haematological, central nerval, psychiatric disease or malignant tumor"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "firstreceived_date": "January 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776697", 
            "org_study_id": "DW330SR-1001(Ver2.2)"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "pelubiprofen (30mg) tablet IR TID, fasting", 
                    "pelubiprofen (30mg) tablet IR TID, fed"
                ], 
                "intervention_name": "pelubiprofen (30mg) tablet IR", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD", 
                "intervention_name": "pelubiprofen SR (as a pelubiprofen 90 mg) tablet", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 23, 2013", 
        "official_title": "A Randomized, Open-labeled, Comparative 3-way Crossover Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC of pelubiprofen(30mg) tablet IR TID", 
                "time_frame": "0, 1, 2, 8, 9, 15, 16, 22 day"
            }, 
            {
                "measure": "AUC of pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD", 
                "time_frame": "0, 1, 2, 8, 9, 15, 16, 22 day"
            }, 
            {
                "measure": "Cmax of pelubiprofen(30mg) tablet IR TID", 
                "time_frame": "0, 1, 2, 8, 9, 15, 16, 22 day"
            }, 
            {
                "measure": "Cmax of pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD", 
                "time_frame": "0, 1, 2, 8, 9, 15, 16, 22 day"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776697"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Daewon Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daewon Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}